Therefore, vemurafenib was developed conjointly with the cobas 4800 BRAF V600 Mutation Test (Roche Molecular Diagnostics) using allele-specific real-time polymerase chain reaction (PCR) and TaqMelt technology to determine BRAF V600 mutation status in DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue [20]. This evidence concerns the gene BRAF and neoplasm.